Dianthus Therapeutics, Inc. /DE/ (DNTH)
Dianthus Therapeutics, Inc. /DE/ (DNTH) from its SEC filings: 2025 revenue $2.0 million (-67% vs the year before), net margin -7973%, free cash flow -$129.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $2.0 million |
| Revenue growth | -67% |
| Net income | -$162.3 million |
| Net margin | -7973.3% |
| Free cash flow | -$129.1 million |
| Diluted EPS | $-4.20 |
| Latest quarter (Q3 2025 (calendar)) revenue vs a year earlier | -82% |
| Cash | $110.5 million |
| Share count, 1 year | +74% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.